Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its management team's participation in four upcoming investor conferences in early 2025. The schedule includes:
- Guggenheim SMID Cap Biotech Conference on February 6, 2025 (Fireside Chat at 1:00 PM ET)
- Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (Fireside Chat at 10:40 AM ET)
- TD Cowen 45th Annual Health Care Conference on March 4, 2025 (Fireside Chat at 1:50 PM ET)
- Leerink Partners Global Healthcare Conference on March 11, 2025 (Fireside Chat at 10:00 AM ET)
Live webcasts and archived recordings of these events will be accessible through the "Events and Publications" tab on Centessa's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CNTA
In the trading session that priced this news, CNTA gained 1.04%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Guggenheim SMID Cap Biotech Conference
Date: February 6, 2025
Fireside Chat: 1:00 PM ET
Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: February 12, 2025
Fireside Chat: 10:40 AM ET
Event: TD Cowen 45th Annual Health Care Conference
Date: March 4, 2025
Fireside Chat: 1:50 PM ET
Event: Leerink Partners Global Healthcare Conference
Date: March 11, 2025
Fireside Chat: 10:00 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. We are developing potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and excessive daytime sleepiness (EDS) in neurological, neurodegenerative, and psychiatric conditions. We also anticipate that our OX2R agonists may have utility in treating impaired attention, cognitive deficits, fatigue, and other symptoms. Our earlier stage pipeline is focused on immuno-oncology with our proprietary LockBody technology platform.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
